UK markets open in 1 hour 52 minutes

Apontis Pharma AG (APPH.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
10.90-0.40 (-3.54%)
At close: 03:43PM CEST
Full screen
Previous close11.30
Open11.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range10.90 - 11.00
52-week range10.40 - 27.30
Volume290
Avg. volume127
Market cap92.65M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed

    DGAP-News: APONTIS PHARMA AG / Key word(s): Half Year Report/Half Year ResultsAPONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed 11.08.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed Revenue from Single Pills +26.0% to EUR 17.7 million remains a key growth driver Single Pill share of revenue increases to 62.9% (H1 20

  • EQS Group

    APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a single pill with pan-European intellectual property rights

    DGAP-News: APONTIS PHARMA AG / Key word(s): Alliance/Market launchAPONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a single pill with pan-European intellectual property rights 19.07.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a single pill with pan-European intellectual property rights Further expansion of the mi

  • EQS Group

    APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis

    DGAP-News: APONTIS PHARMA AG / Key word(s): Market launchAPONTIS PHARMA rolls out new Single Pill for secondary prophylaxis 06.07.2022 / 07:30 The issuer is solely responsible for the content of this announcement.APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis RosuASS provides medium-term annual revenue potential of EUR 2.5 million Potential patient group of more than 100,000 individuals All three targeted single pill launches realized in 2022Monheim am Rhein, 6 July 2022. APO